Amerikanische Gesellschaft für Hirudotherapie

The effects of a hirudin/liposome complex on a diabetic nephropathy rat model

Basic science / preclinical published in BMC complementary and alternative medicine (2019)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
ArzneimittelentwicklungKlinische StudienGenomik & ProteomikSicherheit & InfektionskontrolleWang H et al. · BMC complementary and alternative medicine, 2019

Abstract

BACKGROUND: Hirudin, an extract from Hirudo spp., is an anticoagulant used to treat a variety of renal diseases, including diabetic nephropathy (DN). Currently, hirudin has to be used at high dosages to treat DN because it poorly targets the kidneys, although at high dosages it can have severe side effects. Developing a targeted drug delivery system for hirudin, then, could boost its positive therapeutic effects while lowering the risk of side effects. Liposomes have been demonstrated to have significant renal targeting potential, but here we show that a hirudin-loaded liposome is an effective delivery method for patients with DN. METHOD: In this study, we prepared a hirudin/liposome complex and tested its efficacy by injecting it into a rat model. We then compared the renal accumulation of hirudin between complex-injected rat models and rat models that received injections of hirudin alone. We also investigated the mechanisms behind the complex's effects. RESULT: The hirudin/liposome complex increased the accumulation of hirudin in kidney tissues and relieved the renal injury in DN rat models. Moreover, the hirudin/liposome complex down-regulated the expression of TGF-β1 and VEGF in the kidneys. CONCLUSION: We demonstrated that a hirudin/liposome complex can have a significant positive effect on DN. The mechanism may be that the complex inhibits the expression of VEGF and TGF-β1.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAnimalsBlood GlucoseDiabetes Mellitus, ExperimentalDiabetic NephropathiesDrug Evaluation, PreclinicalFibrinolytic AgentsHirudinsKidneyKidney Function TestsLiposomesMaleRats, Sprague-Dawley

Zusammenfassung

Hirudin, an extract from Hirudo spp. , is an anticoagulant used to treat a variety of renal diseases, including diabetic nephropathy (DN).

Warum dies für die Hirudotherapie relevant ist

Relevant to the development and clinical application of leech-derived pharmaceutical compounds.

Zitation

The effects of a hirudin/liposome complex on a diabetic nephropathy rat model.

Wang H et al. · BMC complementary and alternative medicine, 2019

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: March 18, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.